Source-grounded facts extracted from IMMUNIC, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Erik Lundgren was appointed as Chief Executive Officer at IMMUNIC, INC..
“On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the "Company") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.”
Simona Skerjanec changed role as Member of the Board at IMMUNIC, INC..
“Simona Skerjanec, who has been serving as Interim Chairperson since February 2026, will transition from Interim Chairperson and continue to serve as a member of the Board.”
Michael W. Bonney was appointed as Chair of the Board at IMMUNIC, INC..
“appointed Michael W. Bonney as Chair of the Board, effective immediately.”
IMMUNIC, INC. reported financial results for first quarter ended March 31, 2026.
“On May 13 2026, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended March 31, 2026, and providing a corporate update”
Michael A. Panzara was appointed as Chief Medical Officer at IMMUNIC, INC..
“Immunic, Inc. (the "Company") appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer of the Company, effective immediately.”
IMMUNIC, INC.: Certificate of Amendment filed to effect a 1-for-10 reverse stock split, combining every 10 shares of common stock into 1 share (effective 2026-04-22).
“On April 22, 2026, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to amend the Company’s certificate of incorporation, as amended and restated (the “Charter”), with the Secretary of State of the State of Delaware to effect the Reverse Stock Split at a 1-for-10 ratio”
IMMUNIC, INC. issued warrant to certain accredited investors for aggregate gross proceeds to the Company from the issuance and sale of the Warrants is expected to be approximately $200 million.
“Warrant is exercised, and (iii) February 17, 2031. The aggregate gross proceeds to the Company from the issuance and sale of the Warrants is expected to be approximately $200 million, before deducting fees to be paid to the placement agents and financial advisors of the Company and other estimated offering expenses payable by the Company. The aggregate”
IMMUNIC, INC. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $200 million (effective 2026-02-12).
“On February 12, 2026, Immunic Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), pre-funded warrants”
IMMUNIC, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).
“al Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. As previously disclosed, on June 27, 2025, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Bid Price Rule”). The Company was given a 180-day grace period, until December 24, 2025, to regain compliance with the rule. The Company had no”
IMMUNIC, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“June 27, 2025, Immunic, Inc. (the "Company") received a written notification (the “Notice Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that we were not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our common stock was below the $1.00 per share requirement for the last 30 consecutive business days. The Notice Letter stated that we have 180 calendar days, or until December 24, 2025 (the “Initial Compliance Period”), to regain compliance with the minimum bid price requirement. If we do not regain compliance by the end of the Initial”
Simona Skerjanec was appointed as Director at IMMUNIC, INC..
“On July 24, 2024, Immunic, Inc. (the “Company”) announced the appointment of Simona Skerjanec, M.Pharm, MBA, as a member of the board of directors (the “Board”) of the Company, effective as of July 22, 2024.”
Werner Gladdines changed role as Chief Development Officer at IMMUNIC, INC..
“promotion of Werner Gladdines from Vice President, Program Management & Clinical Development Operations to Chief Development Officer of the Company.”
Jason Tardio was appointed as Chief Operating Officer and President at IMMUNIC, INC..
“appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024.”
IMMUNIC, INC. reported financial results for the first quarter ended March 31, 2024.
“On May 8, 2024, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update”
IMMUNIC, INC.: Increased authorized shares of common stock from 130,000,000 to 500,000,000 (effective 2024-03-06).
“the stockholders of Immunic, Inc. (the "Company") approved an amendment to Article Four, Part A of the Company's Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock, $0.0001 par value per share (the "Common Stock"), from 130,000,000 shares of Common Stock to 500,000,000 shares of Common Stock (the "Amendment"). The Amendment did not change the number of shares of preferred stock that the Company is authorized to issue. On March 5, 2024, the Company filed the Amendment with the Secretary of State of the State of Delaware, which became effective on March 6, 2024.”
IMMUNIC, INC. shareholders approved Approval of the repricing of certain outstanding stock options having exercise price above $3.00 per share to the greater of $1.72 and 110% of closing price on a future repricing date. at the 2024-03-04 meeting.
“Proposal 4: Approval of the Repricing of Certain Outstanding Stock Options FOR AGAINST ABSTAIN BROKER NON-VOTES 48,849,469 11,026,993 216,666 0”
IMMUNIC, INC. shareholders approved Amendment to the 2019 Omnibus Equity Incentive Plan, as amended, to increase shares authorized by 9,100,000 to a total of 19,448,871. at the 2024-03-04 meeting.
“Proposal 3: Approval of an Amendment to the Company’s 2019 Omnibus Equity Incentive Plan, as Amended FOR AGAINST ABSTAIN BROKER NON-VOTES 52,994,383 6,866,888 231,857 0”
IMMUNIC, INC. shareholders approved Amendment to the Amended and Restated 2021 Employee Stock Purchase Plan to increase shares reserved by 1,000,000 to a total of 1,200,000. at the 2024-03-04 meeting.
“Proposal 2: Approval of an Amendment to the Company’s Amended and Restated 2021 Employee Stock Purchase Plan FOR AGAINST ABSTAIN BROKER NON-VOTES 59,279,567 757,471 56,090 0”
IMMUNIC, INC. shareholders approved Amendment to the Amended and Restated Certificate of Incorporation to increase authorized shares of Common Stock from 130,000,000 to 500,000,000. at the 2024-03-04 meeting.
“Proposal 1: Approval of an Amendment to the Company’s Amended and Restated Certificate of Incorporation FOR AGAINST ABSTAIN BROKER NON-VOTES 59,487,494 397,612 208,022 0”
IMMUNIC, INC. reported financial results for the fourth quarter and year ended December 31, 2023.
“Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.”
IMMUNIC, INC. reported financial results for the third quarter ended September 30, 2023.
“On November 14, 2023, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a corporate update”
IMMUNIC, INC. reported financial results for the quarter ended June 30, 2023.
“On August 3, 2023, Immunic, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2023”
IMMUNIC, INC. shareholders approved Approve amendments to the Company's 2019 Omnibus Plan to (i) increase the number of common stock authorized for issuance by 4,440,000 shares to a total of 10,348,871 shares, and (ii) remove the evergreen provision at the 2023-06-28 meeting.
“Proposal 3: Approve Amendments To the Company’s 2019 Omnibus Plan FOR AGAINST ABSTAIN BROKER NON-VOTES 19,529,897 408,815 26,626 5,651,018”
IMMUNIC, INC. shareholders approved Ratification of the selection of Baker Tilly Virchow Krause, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-28 meeting.
“Proposal 2: Ratification of Appointment of Baker Tilly Virchow Krause, LLP as Independent Registered Public Accounting Firm FOR AGAINST ABSTAIN BROKER NON-VOTES 25,469,440 75,616 71,300 0”
IMMUNIC, INC. shareholders approved Election of Dr. Richard Rudick and Ms. Maria Törnsén as directors for a three year term expiring at the 2026 annual meeting of stockholders at the 2023-06-28 meeting.
“Proposal 1: Election of Directors NOMINEE FOR WITHHELD BROKER NON-VOTES Dr. Richard Rudick 19,855,497 109,841 5,651,018 Ms. Maria Törnsén 19,840,786 124,552 5,651,018”
IMMUNIC, INC. reported financial results for first quarter ended March 31, 2023.
“On May 11, 2023, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and providing a corporate update (the “Press Release”).”
Dr. Vincent Ossipow departed as Director at IMMUNIC, INC..
“Additionally, on April 26, 2023, Dr. Vincent Ossipow notified the Board that he plans to retire from the Board at the end of his current term and will not stand for re-election at the 2023 Annual Meeting.”
Dr. Richard Rudick was appointed as Director at IMMUNIC, INC..
“On April 27, 2023, Immunic, Inc. (the “Company”) announced the appointment of Dr. Richard Rudick as a member of the Board of Directors (the “Board”) of the Company, effective as of April 26, 2023.”
IMMUNIC, INC. reported financial results for the quarter and year ended December 31, 2022.
“On February 23, 2023, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter and year ended December 31, 2022 and providing a corporate update (the “Press Release”).”
IMMUNIC, INC. reported financial results for the third quarter ended September 30, 2022.
“On November 3, 2022, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and providing a corporate update”
Jan Van den Bossche resigned as Director at IMMUNIC, INC..
“The Company also announced that current Class III director, Jan Van den Bossche, will be resigning from the Board. The Board accepted Mr. Van den Bossche’s resignation effective July 5, 2022.”
Monika Maria Törnsén was appointed as Director at IMMUNIC, INC..
“On July 5, 2022, Immunic, Inc. (the “Company”) announced the appointment of Monika Maria Törnsén as a member of the Board of Directors (the “Board”) of the Company, effective as of July 5, 2022.”
Glenn Whaley was appointed as Chief Financial Officer at IMMUNIC, INC..
“On March 10, 2022, Glenn Whaley was appointed Chief Financial Officer ("CFO") of the Company.”
Patrick Walsh was appointed as Chief Business Officer at IMMUNIC, INC..
“On October 14, 2021, the board of directors (the “Board”) of Immunic, Inc. (the “Company”) appointed Patrick Walsh as the Chief Business Officer, effective October 14, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.